Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.6% – Here’s What Happened

Shares of Eli Lilly and Company (NYSE:LLY) traded up 1.6% during mid-day trading on Wednesday . The stock traded as high as $1,093.28 and last traded at $1,081.3440. 2,581,749 shares traded hands during trading, a decline of 19% from the average session volume of 3,189,602 shares. The stock had previously closed at $1,064.15.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Health’s move to make WeightWatchers Med+ available through LillyDirect underscores Eli Lilly’s growing influence in the chronic weight-management market and could help support more demand for its GLP-1 ecosystem. CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors
• Positive Sentiment: WW International said its Weight Watchers Med+ program is now accessible through LillyDirect, which expands Lilly’s digital health platform and reinforces its position in GLP-1-based obesity treatment access. Why WeightWatchers (WW) Stock Is Trading Up Today
• Positive Sentiment: Lilly continues to draw upbeat investor attention for its pipeline and growth strategy, with recent coverage highlighting gene editing, vaccines, and cancer as additional upside drivers beyond obesity drugs. Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals
• Positive Sentiment: Eli Lilly also announced a $1.9 billion partnership with Ascidian Therapeutics focused on kidney disease therapies, signaling continued dealmaking and pipeline diversification. Eli Lilly continues genetic medicine push with 1.9bn Ascidian partnership
• Neutral Sentiment: Analyst commentary and stock-picking articles continue to place LLY among top healthcare and pharmaceutical ideas, reflecting generally constructive sentiment but no new company-specific catalyst. The Zacks Analyst Blog Highlights Berkshire, Eli Lilly, Walmart, Universal Health Realty Income and Utah
• Negative Sentiment: Competition in the GLP-1 space remains intense, with rival programs and distribution partnerships increasing pressure on Eli Lilly to defend its obesity-market dominance. HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic’s AI Leap As Lilly, WeightWatchers Turn Up The Heat

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Morgan Stanley reissued an “overweight” rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 1st. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Finally, Weiss Ratings downgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Stock Performance

The company has a 50-day moving average price of $970.24 and a two-hundred day moving average price of $1,012.19. The stock has a market capitalization of $1.07 trillion, a P/E ratio of 40.54, a PEG ratio of 1.18 and a beta of 0.53. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. During the same period last year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently added to or reduced their stakes in the business. Norges Bank bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $12,976,634,000. Capital Research Global Investors increased its holdings in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. J. Stern & Co. LLP increased its holdings in shares of Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after buying an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. raised its position in shares of Eli Lilly and Company by 876.1% during the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after buying an additional 2,131,734 shares in the last quarter. Finally, Fifth Third Bancorp lifted its holdings in shares of Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after acquiring an additional 1,497,423 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.